Stephen Eyre, MD
Urology · Needham, MANPI 1417129826
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $16,688 of the $17,340 with a category attached, or 96.2%. Boston Scientific accounts for 86.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $7,151 and has fallen 66.8% since, to $2,371 in 2024.
Across 21 payments — averaging $825.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$15K
- Beckman Coulter, Inc.$2K
- Urogen Pharma, Inc.$179
- Procept Biorobotics Corporation$173
- Bioprotect Medical, Inc.$20
What the payments were for
- Consulting fees$16,68896%
- Travel & lodging$2812%
- Food & beverage$3712%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $14,969 |
| Beckman Coulter, Inc. | 1 | $2,000 |
| Urogen Pharma, Inc. | 1 | $179 |
| Procept Biorobotics Corporation | 1 | $173 |
| Bioprotect Medical, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$7,688
- Moses 550 D\F\L$2,400
- DXI 9000 Access Immunoassay Analyzer$2,000
- JELMYTO$179
- AQUABEAM SYSTEM$173
How this compares
$17,340 in reported general payments places this provider in the 85th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 43 | $37,040 |
| MyrbetriqMirabegron | 45 | $24,283 |
| JatenzoTestosterone Undecanoate | 11 | $12,136 |
| Tamsulosin Hcl | 612 | $10,400 |
| Methenamine Hippurate | 84 | $8,656 |
| Solifenacin Succinate | 64 | $5,561 |
| Finasteride | 341 | $5,046 |
| Trospium Chloride | 56 | $3,848 |
| Trospium Chloride ErTrospium Chloride | 11 | $2,785 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 23 | $2,713 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 118 | $2,700 |
| Potassium Citrate ErPotassium Citrate | 28 | $2,547 |
| Silodosin | 24 | $2,461 |
| Cefpodoxime Proxetil | 68 | $2,033 |
| Tolterodine Tartrate ErTolterodine Tartrate | 22 | $1,828 |
Paid to pharmacies, not to this prescriber.
Other urology in Needham
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
- Louis LiouCambridge$278K
- Tony LuongoBoston$265K
- Ricardo MunarrizBoston$118K
- Andrew KramerHyannis$108K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.